Cheek Lift — Cost, Top Hospitals & Success Rates | MyMedicPlus

The cheek lift — also termed midface lift or malar lift — is a facial rejuvenation procedure targeting the ptotic (descended) soft tissues of the midface: the malar fat pad, orbicularis oculi muscle, and subcutaneous tissue that with ageing descend from the cheekbones inferiorly, deepening the nasolabial folds, creating infraorbital hollowing (the tear trough deformity), and flattening the once-convex youthful malar eminence into a sagging, flat midface contour. The procedure vertically repositions these descended soft tissues back onto the malar skeleton, recreating the high, full cheekbone contour of youth.

Unlike the lower facelift, which addresses jowling and neck laxity, or brow lift, which addresses forehead and periorbital ageing, the cheek lift specifically targets the middle third of the face — the area between the lower eyelid and the upper lip that is notoriously difficult to rejuvenate with non-surgical treatments alone. A well-performed cheek lift dramatically reduces the nasolabial fold depth, softens the nasojugal groove (tear trough), restores malar projection, and reduces the appearance of jowling by elevating the tissue that contributes to the jowl-nasolabial fold complex.

Cheek lifts can be performed as isolated procedures but are most commonly performed in combination with blepharoplasty (eyelid surgery), facelift, and fat transfer for comprehensive facial rejuvenation. Approaches vary — endoscopic, SMAS (superficial musculoaponeurotic system) manipulation, sub-periosteal dissection, or composite flaps that include the orbicularis muscle — and are selected based on patient anatomy, surgeon expertise, and the degree and distribution of ageing changes present.

Age-related midface descent with deepening nasolabial folds, malar flattening, and tear trough hollowing is the primary indication for cheek lift surgery. In younger patients (typically aged 35–50), malar soft tissue ptosis may precede significant jowling and neck ageing, making an isolated or endoscopic cheek lift appropriate without the need for a full facelift. In older patients (typically 50–70), cheek lift is most commonly performed as a component of a comprehensive face and neck rejuvenation procedure incorporating SMAS plication or SMAS lifting techniques.

Post-blepharoplasty secondary corrections where previous lower eyelid surgery has created a hollowed infraorbital appearance may also benefit from a midface lift that restores volume and tissue support beneath the lower eyelid. Facial paralysis from Bell's palsy or other causes producing unilateral midface ptosis and nasolabial fold effacement on the paralysed side may be addressed with a static facial suspension or dynamic reanimation procedure targeting the cheek region. Cleft lip nasal deformity reconstruction in adults sometimes incorporates cheek-lip complex repositioning as part of the secondary rhinoplasty and lip revision.

Ideal candidates for cheek lift surgery are adults in good general health with visible midface ageing — flattened cheekbones, deepened nasolabial folds, infraorbital hollow, and cheek ptosis — who have realistic expectations and understand that a cheek lift rejuvenates the midface but does not address neck laxity, perioral lines, or brow ptosis. Age range is typically 40–70 years, though some patients in their mid-to-late 30s with premature midface ageing from significant weight loss are appropriate candidates. Non-smokers or patients who have successfully quit smoking for at least four weeks before surgery have significantly lower wound healing complication rates and are preferred.

Contraindications include active bleeding disorders or anticoagulant use that cannot be safely bridged, active facial skin infection or rosacea in an inflammatory phase, previous aggressive facial surgeries that have altered anatomical planes (particularly failed or complicated prior midface procedures), and unrealistic expectations. Thin-skinned patients and those with very little subcutaneous tissue are at higher risk of skin irregularities. Patients with significant lower eyelid laxity (a positive snap test) should have this corrected concurrently or sequentially to avoid post-operative lower eyelid retraction after midface elevation.

The endoscopic midface lift uses three small incisions — temporal, oral, and lower eyelid — and a 30-degree endoscope to visualise the sub-periosteal dissection plane. The cheek tissues are mobilised off the malar bone in the sub-periosteal plane and vertically elevated and fixated using endoscopic fixation devices (Endotine Midface, Brow Lift System). This approach avoids visible scars on the face, minimises skin undermining, and has a faster recovery than open approaches, making it popular in younger patients with early-moderate midface ptosis. The main limitation is that it provides predominantly vertical repositioning with limited SMAS manipulation and may be insufficient for more advanced ageing.

Composite and SMAS-based midface lifts incorporate the midface dissection into a lower facelift approach through a preauricular incision. The SMAS flap is elevated to include the malar fat pad, providing a composite lift that repositions the entire malar-facial soft tissue unit. Sub-periosteal dissection from a facelift incision provides robust tissue repositioning to the malar skeleton and is favoured for patients with more advanced midface ageing and concurrent lower face ptosis. Thread (suspension) lifts using absorbable or permanent barbed sutures from temporal anchor points represent a minimally invasive alternative — faster recovery, fewer risks, lower cost — but provide less sustained results than surgical approaches and are generally preferred for younger patients or as adjuncts to other procedures.

A well-executed cheek lift provides highly satisfying facial rejuvenation results that are specific to the midface region, filling the aesthetic gap that cannot be adequately addressed by either a facelift (which improves lower face) or a brow lift (which improves the upper face) alone. Key aesthetic improvements include significant flattening of the nasolabial folds, restoration of convex malar fullness, softening of the tear trough deformity, and improved lower eyelid-cheek junction appearance. The results are natural-appearing when anatomy is respected — avoiding the over-corrected, operated appearance of earlier mid-century facelifts.

Longevity of results varies by technique: endoscopic approaches typically last five to eight years; SMAS-based and sub-periosteal approaches typically last ten or more years, as the deep-plane dissection repositions tissues at a structural rather than superficial level. In combination procedures including fat transfer, the improved volume enhances and complements the tissue repositioning, providing a more comprehensive rejuvenation result. Patient satisfaction studies consistently show high contentment with cheek lift when performed as part of a comprehensive facial rejuvenation plan with appropriate candidate selection.

Nerve injury is the most significant risk of cheek lift surgery. The facial nerve branches — particularly the temporal branch (brow elevation) and zygomatic branches (eyelid closure and cheek movement) — run in close proximity to the dissection planes of a cheek lift and can be stretched, contused, or divided during surgery. Transient weakness occurs in approximately 5–10% of cases and almost always resolves within six to twelve weeks; permanent facial nerve injury is rare below 1% at experienced hands. Infraorbital nerve injury from sub-periosteal dissection near the infraorbital foramen can cause cheek and upper lip numbness, usually transient.

Lower eyelid retraction or ectropion after midface lift is a specific risk, particularly when the lower eyelid approach is used without adequate support of the lower lid by concurrent canthoplasty or lateral tarsal strip procedure. Patients with pre-existing lower eyelid laxity are at highest risk. Contour irregularities from uneven fat pad repositioning, asymmetry from differential healing, and visible suture or fixation device palpability are aesthetic complications reported in 3–8% of cases. Haematoma formation, requiring surgical drainage, occurs in 1–3% of cases; infection requiring antibiotic or surgical management in 1–2%.

After cheek lift surgery, patients are discharged on the day of or after overnight observation. Significant swelling, bruising, and tightness of the cheeks and lower eyelid region peaks at three to five days and substantially resolves over two to four weeks. Cool compresses, head elevation, and avoidance of straining reduce swelling intensity in the immediate post-operative period. Temporary sensory changes — numbness, tingling, or hypersensitivity of the cheek, upper lip, or lower eyelid region — are expected and typically resolve within six to twelve weeks.

Return to social activities (with swelling and bruising largely concealed by make-up) typically occurs at two to three weeks; return to physical exercise at four to six weeks. Sun protection is critical for the first six to twelve months to prevent hyperpigmentation of healing incision sites. Final aesthetic results are assessable at three to six months when all swelling has resolved and tissues have settled. Patients with concurrent SMAS facelift or blepharoplasty follow additional recovery instructions relevant to those components. Follow-up visits at one week, one month, and three to six months are standard.

An isolated endoscopic cheek lift in the United States costs USD 6,000–12,000 including surgeon, anaesthesia, and facility fees. Combined cheek and facelift procedures cost USD 15,000–30,000. UK private prices for an isolated midface lift are GBP 5,000–12,000. In India, cheek lift surgery at Apollo Cosmetic Clinics, Fortis Aesthetic Centre, or specialist private plastic surgeons costs USD 2,000–5,000; combined procedures USD 5,000–12,000 — representing 60–75% savings versus US prices.

Thailand, particularly Bangkok with its highly developed aesthetic surgery infrastructure at hospitals such as Bumrungrad, Bangkok Hospital, and Bangpakok International, charges USD 4,000–9,000 for a cheek lift and USD 8,000–18,000 for combination face/cheek lift procedures. Turkey (Istanbul aesthetic surgery centres) charges USD 3,000–8,000. Mexico (Monterrey, Mexico City) USD 3,000–7,000. South Korea, renowned for facial aesthetic surgery, charges USD 5,000–12,000 for midface procedures. International patients often combine multiple procedures — rhinoplasty, blepharoplasty, cheek lift, fat transfer — for comprehensive facial rejuvenation at substantial overall savings versus US prices.

Non-surgical midface rejuvenation with dermal fillers — hyaluronic acid (Juvederm Voluma, Restylane Lyft) or poly-L-lactic acid (Sculptra) — is the most widely used alternative to cheek lift surgery, providing immediate volume restoration, softening of nasolabial folds, and enhanced malar projection without surgery or downtime. Results last twelve to twenty-four months and are reversible with hyaluronidase enzyme. Fillers are appropriate for patients with mild-to-moderate midface volume loss and ptosis, for patients not yet ready for surgery, or for those seeking a non-surgical preview of surgical outcomes. High-intensity focused ultrasound (HIFU, Ultherapy) and monopolar radiofrequency (Thermage) stimulate dermal collagen and provide modest skin tightening with one to two year longevity — appropriate for mild tissue laxity in younger patients. Thread lifts with PDO or PCL barbed sutures provide temporary mechanical suspension of descended tissues — modest lifting, two to three year duration, fewer risks than surgery but less dramatic and less sustained results.